A recent large cohort study confirmed that approximately 40% of SSc patients harbor anti-M3R antibodies, with high-titre positivity associated with diffuse cutaneous disease, clinically severe GI involvement and anti-RNPC3 (U11/U12) and/or U1RNP positivity [13,36]. This evidence concerns the gene RNPC3 and systemic sclerosis.